Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-Dose Daptomycin vs Vancomycin for MRSA Bacteremia
NCT00695903Phase 2Terminated
- Sponsor
- Merck & Co.
- Start
- Sep 2008
- Primary completion
- Aug 2010
- Modality
- Cyclic Peptides, Antimicrobial Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of daptomycin in Staphylococcus aureus bacteremia (SAB), right-sided infective endocarditis (RSIE), sponsored by Merck & Co.. Started Sep 2008; status: terminated.
02
Drugs
daptomycin
03
Conditions
Staphylococcus aureus bacteremia (SAB)right-sided infective endocarditis (RSIE)
Beyond the preview
Go deeper on NCT00695903.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00695903.